Security key
95075A107
Werewolf Therapeutics, Inc. - Common Stock, $0.0001 par value per share (HOWL)
CUSIP: 95075A107
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 21,108,242
- Total 13F value
- $41,572,612
- Share change
- -1,193,221
- SEC-reported price per share
- $1.97
- Number of holders
- 62
- Value change
- -$2,103,204
- Number of buys
- 18
- Number of sells
- 29
- Shares outstanding
- 48,427,829
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
62
Top holders
10
HOWL full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Previous quarter: Q2 2025
Werewolf Therapeutics, Inc. SEC filings
Werewolf Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 95075A107
Recent filing periods:
Ownership snapshot
Top reported holders of HOWL - Werewolf Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
PFM Health Sciences, LP
Disclosed value leader
RA CAPITAL MANAGEMENT, L.P.
Comparable rows
15/15
Latest evidence
30 Jun 2025
13F
13D/G
Lead comparable stake: 0.9%
13D/G row: PFM Health Sciences, LP
Showing 1-6 of 15 holder rows.
Quick read
PFM Health Sciences, LP leads the comparable SEC ownership view at 0.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens PFM Health Sciences, LP's linked filing trail.
Comparable ownership
Top 5
PFM Health Sciences, LP
0.9%
RA CAPITAL MANAGEMENT, L.P.
14%
MPM ASSET MANAGEMENT LLC
8.9%
MPM BioImpact LLC
5%
BANK OF AMERICA CORP /DE/
4.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| PFM Health Sciences, LP |
13F
13D/G
Company
|
0.9%
from 13D/G
|
$437,210
401,110 shares
|
— | 30 Jun 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
14%
|
$7,282,625
6,681,307 shares
|
— | 30 Jun 2025 |
| MPM ASSET MANAGEMENT LLC |
13F
Company
|
8.9%
|
$4,697,747
4,309,860 shares
|
— | 30 Jun 2025 |
| MPM BioImpact LLC |
13F
Company
|
5%
|
$2,625,603
2,408,810 shares
|
— | 30 Jun 2025 |
| BANK OF AMERICA CORP /DE/ |
13F
Company
|
4.4%
|
$2,320,636
2,129,024 shares
|
— | 30 Jun 2025 |
| VANGUARD GROUP INC |
13F
Company
|
2.7%
|
$1,415,094
1,298,251 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
62
Shares
21,108,242
Rows available
62
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
65
Q3 2025 holders
62
Holder diff
-3
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend